|
| Research progress of CYP2C19 genotype with myocardial injury and long-term major adverse cardiovascular events after percutaneous coronary intervention |
| Received:August 22, 2017 Revised:September 22, 2017 |
| View Full Text View/Add Comment Download reader |
| DOI：10.11915/j.issn.1671-5403.2018.04.070 |
| Key words:genotype myocardial injury clopidogrel resistance percutaneous coronary intervention major adverse cardiovascular events |
|
| Hits: 1146 |
| Download times: 885 |
| Abstract: |
| Dual antiplatelet therapy is recommended for coronary heart disease patients after percutaneous coronary intervention (PCI) so as to reduce the risk of major adverse cardiovascular events (MACE). However, some patients do not display adequate antiplatelet response and show resistance to clopidogrel, which seriously affecting the prognosis of them. Therefore, it is a practical problem for the relationship between CYP2C19 genetic polymorphisms and myocardial injury after PCI as well as long-term MACE. We reviewed the problem in this article. |
| Close |